PubRank

H N Magnani

Author PubWeight™ 18.41‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet 1987 1.25
2 A study of methods of identification and estimation of Lp(a) lipoprotein and of its significance in health, hyperlipidaemia and atherosclerosis. Atherosclerosis 1974 1.04
3 Glaucoma and ischaemic vascular disease risk factors. Trans Ophthalmol Soc U K 1976 0.95
4 ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man. Br J Clin Pharmacol 1987 0.91
5 Use of a heparinoid in patients with hemorrhagic stroke and thromboembolic disease. Ann Neurol 1984 0.89
6 Peptide composition of human plasma apolipoproteins A, B and C. Expos Annu Biochim Med 1972 0.83
7 Identification of lipoprotein families in familial lecithin: cholesterol acyltransferase deficiency. Biochim Biophys Acta 1973 0.82
8 A method for the quantitative determination of the abnormal lipoprotein (LP X) of obstructive jaundice. Clin Chim Acta 1972 0.82
9 Orgaran in heparin-induced thrombocytopenia. Haemostasis 1992 0.81
10 Utilization of the quantitative assay of lipoprotein X in the differential diagnosis of extraphepatic obstructive jaundice and intrahepatic diseases. Gastroenterology 1976 0.81
11 Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Haemostasis 1992 0.79
12 Apolipoproteins and lipoprotein families in familial lecithin: cholesterol acyltransferase deficiency. Scand J Clin Lab Invest Suppl 1974 0.79
13 Heparin-induced thrombocytopenia in paediatric patients--a review of the literature and a new case treated with danaparoid sodium. Eur J Pediatr 1999 0.79
14 Danaparoid is not a low-molecular-weight heparin. Am J Hosp Pharm 1994 0.78
15 Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid. Thromb Haemost 1992 0.78
16 Interaction study between Org 10172, a low molecular weight heparinoid, and acetylsalicylic acid in healthy male volunteers. Thromb Haemost 1991 0.77
17 [Danaparoid in pregnancy in cases of heparin intolerance - use in 59 cases]. Hamostaseologie 2007 0.77
18 Quantitative changes of serum lipoprotein-X after cholestyramine administration in infants with cholestatic biliary tract and liver disease. Eur J Clin Invest 1978 0.77
19 A novel assay for the quantitative determination of lipoprotein-X (LP-X) in serum. Clin Chim Acta 1983 0.76
20 A quantitative method for blood lipoproteins using cellulose acetate electrophoresis. J Clin Pathol 1971 0.75
21 Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials. J Neurol Neurosurg Psychiatry 1994 0.75
22 Management of heparin induced thrombocytopenia. BMJ 1993 0.75
23 [Metabolic changes of cholestatic lipoprotein (LP-X) in the diagnosis of biliary atresia]. Cesk Pediatr 1978 0.75
24 Early clinical experience of a new heparinoid, Org 10172, in prevention of deep venous thrombosis. Thromb Res 1987 0.75
25 The effect of sequential mestranol-norethisterone on the circulating lipid levels of pre- and post-menopausal women, and its possible significance. Postgrad Med J 1976 0.75
26 Partial ileal bypass in familial hypercholesterolaemia. Lancet 1981 0.75
27 Proceedings: Obstructive lipoprotein (LP-X) and liver disease. Clin Sci Mol Med 1974 0.75
28 Cholestatic jaundice in infancy diagnosis, differential diagnosis and treatment. Aust Paediatr J 1976 0.75
29 Existence of alkaline phosphatase-lipoprotein X complex questioned. Clin Chem 1981 0.75
30 The influence of LP-X and other lipoproteins associated with hepatic dysfunction on the activity of lecithin:cholesterol acyltransferase. Biochim Biophys Acta 1976 0.75
31 Heparin-induced thrombocytopenia: an under-diagnosed syndrome? Proceedings of a workshop held in London on 1 November 1996. Consensus overview. Platelets 1997 0.75